Abstract Alendronate (AL) is commonly used for the prevention and treatment of osteoporotic fractures. Little is known about the effects of AL administration on osteoclast differentiation from human marrow progenitor cells. We used marrow discarded during orthopedic surgery to test the hypothesis that cultures of bone marrow-derived stem cells (BMCs) from subjects receiving AL (?AL) may differ from control subjects with respect to in vitro osteoclast differentiation and regulatory factors. The number of osteoclasts generated in BMC cultures from control subjects was 4.7-fold greater than that from ?AL subjects (P = 0.015). RANKL expression in ?AL BMCs was 57% of that in controls (P = 0.001), and OPG expression in ?AL BMCs was greater than in controls (153%, P = 0.01). The mean RANKL/OPG ratio in BMCs was 0.65 ± 0.35 for ?AL specimens and 1.28 ± 0.53 for controls (P = 0.031). In addition, we assessed the direct effect of AL on expression of RANKL and OPG in marrow stromal cells isolated from nine control women. Treatment with AL downregulated RANKL expression and upregulated OPG expression, with an average 50% decrease in RANKL/OPG ratio at 10 -7 M (P = 0.004). These results show that osteoclast differentiation is dysregulated in marrow isolated from ?AL subjects. Furthermore, AL may inhibit human osteoclastogenesis by affecting the key regulatory genes in marrow cells.
activator of nuclear factor-jB ligand (RANKL) and the inhibitory decoy receptor osteoprotegerin (OPG) [8] .
Amino-bisphosphonates (N-BPs) inhibit bone resorption by inactivating osteoclasts. The major mechanism by which they inhibit bone resorption is by inducing apoptosis of mature osteoclasts [9] . In bone biopsies from women treated with AL, Weinstein et al. [10] described large, multinucleated, apoptotic cells as poorly resorbing and detached from the bone. In vitro, N-BPs induce apoptosis in murine osteoclasts [11] and their progenitors [12] . It has been shown that N-BP inhibition of protein prenylation is the mechanism of the apoptotic effect. After being internalized by osteoclasts, N-BPs inhibit farnesyl pyrophosphate synthase in the mevalonate pathway and block biosynthesis of small GTPases, such as Ras, Rho, and Rab [12, 13] .
There is some evidence that BPs inhibit differentiation of osteoclasts in cultured segments of murine metatarsals [14] . The effects of BPs on human osteoclastogenesis are not clear. One study with human bone marrow cells showed that in vitro treatment with BPs inhibited the formation of osteoclast-like cells [15] . In this study, we tested the hypothesis that bone marrow cells from subjects who were receiving AL may differ from those of control subjects with respect to in vitro osteoclast differentiation and expression of RANKL, OPG, and M-CSF, three key factors that regulate this process. In addition, we tested the direct effect of AL on RANKL and OPG expression in adherent human marrow stromal cells (MSCs).
Materials and Methods

Human Bone Marrow
Bone marrow samples were obtained with institutional review board approval as femoral tissue discarded from postmenopausal female subjects during primary hip arthroplasty for osteoarthritis [16, 17] . Criteria for exclusion were rheumatoid arthritis, cancer, and other comorbid conditions that may influence skeletal metabolism, such as renal insufficiency, alcoholism, active liver disease, malabsorption, hyperthyroidism, ankylosing spondylitis, aseptic necrosis, hyperparathyroidism, morbid obesity, and diabetes. Also excluded were patients who were taking medications other than BPs that may influence skeletal metabolism (e.g., thyroid hormone, glucocorticoids, and NSAIDs).
Bone Marrow Cultures for Osteoclast Differentiation
Marrow from 11 postmenopausal women who were receiving AL at the time of surgery (?AL) and 12 women without history of receiving BPs (control) was used in the first part of the study. All reagents used in these studies were certified by suppliers as endotoxin-free. Low-density bone marrow cells (BMCs) were isolated as previously described [16, 17] . In brief, bone marrow was mixed with Ficoll-Histopaque 1077 (Sigma, St. Louis, MO) and centrifuged to isolate the low-density mononuclear population that is enriched for undifferentiated cells of the adherent mesenchymal and nonadherent hematopoietic lineages. It is common to use density centrifugation to remove mature marrow cells that may influence the progenitors [6, [15] [16] [17] [18] . The seeding density used here (1.4 9 10 6 cells/cm 2 ) was higher than in studies from other laboratories [6, 15] in order to optimize spontaneous generation of osteoclasts. In a preliminary time-course experiment, cells were cultured in 35-mm tissue culture dishes (1.4 9 10 6 cells/cm 2 ) with a-MEM (GIBCO, Grand Island, NY) containing 10% fetal bovine serum-heat inactivated (FBS-HI; Invitrogen, Carlsbad, CA), 100 U/ml penicillin, and 100 lg/ml streptomycin (GIBCO) in a humidified atmosphere of 5% CO 2 and 95% air at 37°C. Cells were incubated with or without ±25 ng/ml recombinant human M-CSF (R&D Systems, Minneapolis, MN) [19] [20] [21] or 100 ng/ml recombinant human sRANKL (Pepro Tech, Rocky Hill, NJ) [22] , and osteoclasts were enumerated at intervals. In subsequent experiments, cells were seeded at 30 9 10 6 in 60-mm tissue culture dishes (1.4 9 10 6 cells/cm 2 ) and incubated with or without ±25 ng/ml M-CSF for 14 days. Some samples were treated with 10 -7 M alendronate (Sigma), a concentration shown to inhibit bone resorption by in vitro generated osteoclasts [23] . Half-medium was changed twice weekly with care to not remove nonadherent cells. Photomicrographs were captured with a Nikon (Tokyo, Japan) inverted photomicroscope with Hoffman modulation contrast optics in order to emphasize cell margins.
Enumeration of Multinucleated Osteoclasts
Cultures were evaluated for development of multinucleated cells positive for tartrate-resistant acid phosphatase (TRAP) stain. In a time-course experiment, BMC cells from control and AL subjects were cultured ± M-CSF (25 ng/ml) for 7, 10, and 14 days, or sRANKL (100 ng/ml) for 14 days. For subsequent 14-day studies, BMC cultures from five control subjects were cultured with or without M-CSF (25 ng/ml) or AL (10 -7 M). BMCs from five ?AL subjects were cultured with or without M-CSF. Cytochemical staining for TRAP was performed. Cultures were washed with phosphate-buffered saline (PBS, GIBCO) and fixed for 15 min with 2% paraformaldehyde. They were rinsed twice with PBS, following which 3 ml of freshly filtered incubation medium (pH 5.0) was added for 45 min at 37°C. Incubation medium consisted of 50 ml 0.1 M acetate buffer, 10 ml 0.3 M sodium tartrate, 1 ml 10 mg/ml naphthol AS-MX phosphate, 100 ll Triton X-100, 38.9 ml distilled water, and 0.3 mg/ml fast red violet LB (Sigma). Plates were rinsed with PBS and coverslipped with GVA Medium (Invitrogen). TRAP-positive multinucleated cells (cells with three or more nuclei) were counted in 90 contiguous fields, each representing an area of 1.23 mm 2 , with a Nikon Labophot microscope. This was done without knowledge of sample identity. The total number was expressed per centimeter squared.
Similar cultures of BMCs from 10 control and seven ?AL subjects were used for RT-PCR evaluation for expression of TRAP, cathepsin-K, RANKL, and OPG genes.
Human MSCs
For the second part of this study, adherent MSCs from nine control female subjects were used. BMC preparations were plated as above, but nonadherent stem cells of the hematopoietic/osteoclast lineage were rinsed away after the first 24 h of culture. Adherent hMSCs were expanded to passage 2 or 3 in 100-mm dishes with a-MEM containing 10% FBS-HI, 100 U/ml penicillin, and 100 lg/ml streptomycin (GIBCO). Upon 80% confluence, hMSCs were treated with AL (10 -7 or 10 -9 M) or 25 ng/ml M-CSF for 3 days. Total RNA was isolated and expression of RANKL, OPG, and M-CSF genes was evaluated.
RNA Isolation and PCR
Total RNA was isolated from dishes of BMCs and hMSCs with Trizol reagent (Invitrogen). For RT-PCR, 2 lg of RNA was reverse-transcribed with Superscript II (Invitrogen) following the manufacturer's instructions. One-twentieth of the cDNA was used in each 50-ll PCR (30-40 cycles), with specific primers including GAPDH [24] , cathepsin-K [25] , TRAP [25] , OPG [24] , RANKL (F:AACACGCGTATTTACAGCC, R:CCCCTTCAGATG ATCCTTCA), and M-CSF (F:ATGACAGACAGGTGGA ACTGCCAGTGTAGAGG, R:TCACACAACTTCAGTA GGTTCAGGTGATGGGC). Concentration of cDNA and amplification conditions were optimized for each gene product to reflect the exponential phase of amplification. PCR products were quantified by densitometry of captured agarose gel images with the Kodak Gel Logic 200 imaging system and measured by the Kodak molecular Imaging System (New Haven, CT). Gene expression was calculated relative to GAPDH.
Statistical Analyses
Data are expressed as means ± standard deviation (SD). Statistical analyses were performed with GraphPad InStat 3 (GraphPad Software, La Jolla, CA). Values were analyzed with paired Student's t-test and Bonferroni correction for multiple comparisons, Wilcoxon matched-pairs signed rank tests, ANOVA, Mann-Whitney test for nonparametric data, and Spearman correlation tests.
Results
Effect of BP Therapy In Vivo on Marrow Differentiation of Osteoclasts In Vitro
A time-course study with cells from control (80-year-old) and ?AL (84-year-old) subjects showed that osteoclasts generated spontaneously (Fig. 1) , due to the establishment of a supportive stromal monolayer. Addition of exogenous M-CSF or sRANKL appeared to increase the number of osteoclasts. In subsequent experiments with more specimens, osteoclasts were enumerated at 14 days ( Table 1) . The mean age of control subjects was 70.4 ± 6.0 years and that of ?AL subjects was 73.8 ± 10.5 years. More osteoclasts were generated in BMC cultures from control subjects (547 ± 295 per cm 2 ) than from ?AL subjects (116 ± 99, P = 0.015). As expected, addition of M-CSF increased the number of osteoclasts in the control group (238%), but with the numbers available this was not statistically significant (P = 0.187, paired t-test) because of one unresponsive specimen. The other samples showed stimulation by M-CSF (Fig. 2a, b) . Addition of M-CSF tended to increase osteoclast numbers in ?AL specimens 5.8-fold, but this was not statistically significant (P = 0.062, paired t-test). Some BMC cultures from control subjects were treated with 10 -7 M AL (Fig. 2c) . The number of osteoclasts generated in the presence of AL was 53% of basal osteoclastogenesis.
More sensitive than enumeration of cells, RT-PCR indices of osteoclast differentiation were determined for a series of BMC cultures from 10 control and seven ?AL Fig. 1 Time course of osteoclast generation in bone marrow cell cultures from control (80-year-old woman) and AL (84-year-old woman) subjects. Some cells were treated with 25 ng/ml M-CSF or 100 ng/ml sRANKL specimens (Fig. 3) . The mean age of control subjects was 70.8 ± 5.4 years and that of ?AL subjects was 73.8 ± 6.8 years. Expression analysis of osteoclast marker genes, TRAP, and cathepsin-K (Cat-K) showed that ?AL samples had lower expression of the osteoclast marker genes Cat-K (32%, P = 0.01) and TRAP (48%, P = 0.06). As expected, M-CSF significantly increased Cat-K and TRAP in both ?AL (Cat-K 2.7-fold, P = 0.005; TRAP 3.3-fold, P = 0.02) and controls (Cat-K 2.5-fold, P = 0.01; TRAP 2.3-fold, P = 0.01).
For a set of 12 samples, data were available for all measures of osteoclastogenesis, including number of TRAPpositive multinucleated cells and expression of the osteoclast marker genes TRAP and Cat-K. Osteoclast cell counts were positively correlated with both osteoclast marker genes, TRAP (P = 0.015) and Cat-K (P = 0.023) (Fig. 4) .
Effect of BP Therapy In Vivo on Marrow Expression of Osteoclast Regulatory Genes In Vitro
Expression of the pro-osteoclastogenic factor RANKL and the antiosteoclastogenic factor OPG was assessed in BMC % Effect AL/basal (P, paired) 53 ± 58 (P = 0.187) Fig. 2 Photomicrograph of representative cultures of cells from a control subject after staining for TRAP activity. Bone marrow cells were cultured for 2 weeks in a basal medium, b basal medium with 25 ng/ ml M-CSF, and c basal medium with 10 -7 M AL. Hoffman modulation contrast optics accentuate nuclear profiles and margins of the cells Fig. 3 Expression of CAT-K, TRAP, RANKL, and OPG after 2-week culture of bone marrow cells from women who were receiving alendronate (?AL, n = 7) and controls (n = 10), with or without 25 ng/ml M-CSF. Data are shown as the mean ± SD for each gene relative to expression of GAPDH. *P = 0.01, **P = 0.001 for AL versus control cultures for which TRAP and Cat-K expression were measured (Fig. 3) . Expression of RANKL in ?AL samples (0.51 ± 0.20) was 57% of that in controls (0.89 ± 0.09, P = 0.001). Expression of OPG in ?AL samples (1.33 ± 0.36) was 153% of that in controls (0.87 ± 0.27, P = 0.01). The means of the RANKL/OPG ratios in BMCs were 0.65 ± 0.35 for ?AL and 1.28 ± 0.53 for controls (P = 0.031). Treatment with M-CSF resulted in suppression of OPG in the ?AL group (50%, P = 0.003) and in eight of 10 controls (62%, P = 0.02).
Effects of AL In Vitro on Expression of Osteoclast Regulatory Genes in Human MSCs
To assess the direct in vitro effect of AL on the factors that regulate osteoclastogenesis, we treated hMSCs from nine control subjects (mean age 67.1 ± 8.1 years) with AL. First, we demonstrated that all samples of hMSCs expressed the pro-osteoclastic factors RANKL and M-CSF and the antiosteoclastic factor OPG during 5 days of culture (data not shown). There was a wide range of basal expression of osteoclast regulatory genes. Basal expression of RANKL ranged 3.8-fold and expression of OPG ranged sevenfold for the nine samples. The mean RANKL/OPG ratio was 1.84 ± 0.40 (Fig. 5) . Analysis of effects of AL on the RANKL/OPG ratio in MSCs showed significant decreases (P = 0.012 at 10 -9 M and 0.004 at 10 -7 M, ANOVA and Wilcoxon matched-pairs signed rank tests). In this experiment, treatment of cells with AL did not have significant effects on M-CSF expression at 1, 3, or 5 days (data not shown).
Discussion
These data show that osteoclast differentiation was diminished in BMC cultures that were isolated from postmenopausal women receiving AL compared with control subjects. It is not entirely surprising that marrow behavior in vitro was correlated with in vivo status of the subjects. Many in vitro studies with human marrow have shown that isolated marrow cells retain aspects of the clinical status of the subject, such as age-related increases in osteoclast differentiation [7] and in osteoclastogenic cytokines [26] ; reduction of those cytokines in cells from women receiving estrogen-replacement therapy [26] ; an age-related decline in OPG expression [24] ; reduced in vitro osteoclast differentiation following parathyroidectomy of a subject with hyperparathyroidism [6] ; age and gender differences in WNT gene expression [27] ; and agerelated differences in proliferation, senescence markers, and osteoblast potential [17] . To our knowledge this is the first study to evaluate BMCs from subjects receiving AL.
Large numbers of TRAP-positive multinucleated osteoclasts were generated spontaneously in BMC cultures from control subjects in basal medium. This is expected because of the high seeding density that was used and because of the advanced age of the subjects whose marrow was studied. We [7, 28] and others [29] have reported that human osteoclast formation with BMCs increases with age.
This study is the first to show that in vivo treatment with AL decreases in vitro differentiation of BMCs to develop into osteoclasts. In contrast to this finding with human cells, Van Beek et al. [30] reported that AL given to mice for 4 weeks suppressed in vivo bone resorption but did not affect the in vitro capacity of isolated bone marrow to develop into bone-resorbing osteoclasts. In a more recent MSCs from nine control subjects were treated with AL at 10 -9 or 10 -7 M for 3 days. Expression levels of RANKL and OPG were normalized to GAPDH; data are presented as the mean ± SEM for the ratios of RANKL/GAPDH to OPG/GAPDH study with a different culture model, Van Beek et al. [14] reported that AL and other N-BPs inhibited in vitro development of bone-resorbing osteoclasts in fetal mouse metatarsals. M-CSF is often used in vitro with marrow cells to stimulate differentiation and activation of osteoclast progenitors [19] [20] [21] . In this study, treatment with M-CSF increased osteoclast differentiation in the control group, as expected. Because addition of M-CSF or RANKL also increased osteoclast differentiation of cells from ?AL subjects, we conclude that suppression of in vitro osteoclastogenesis by in vivo administration of AL was not due to complete obliteration of osteoclast progenitors.
We showed that in vitro treatment with AL reduced generation of osteoclasts in specimens from control subjects. This confirms the only related previous study with human BMC cultures [15] . Studies with coculture models provide different conclusions. Breuil et al. [23] used a coculture model of human peripheral blood mononuclear cells with murine ST2 stromal cells on bone slices and reported that AL inhibited bone resorption at C10 -7 M but with an inconsistent effect on osteoclast number. Murakami et al. [31] , using cocultures of murine marrow and osteoblasts, concluded that AL inhibited osteoclastic resorption but did not inhibit murine osteoclast recruitment. Both of those studies supplemented the medium with 1a,25-dihydroxyvitamin D 3 , which may alter responses to AL. There may be different effects for different N-BPs and differences attributable to species or source of osteoclast progenitors.
These experiments do not reveal the contribution of AL's inhibition of osteoclastogenesis to its net effects on bone in vivo. In a recent analysis of bone biopsies from subjects in an AL trial, Weinstein et al. [10] reported an unexpected apparent increase in the number of osteoclasts, including distinctive giant, hypernucleated, detached, and apoptotic osteoclasts, in samples from subjects treated with 10 mg/day AL compared with placebo. Because markers of bone resorption were reduced in the treated group, the authors concluded that the osteoclast number was not an index of bone resorption and that the observed osteoclasts were not functionally resorptive. They speculated that AL may prolong the duration of osteoclast apoptosis. The in vitro findings described herein of reduced osteoclast differentiation with marrow from subjects receiving AL may appear to contrast with the biopsy findings. We speculate that there may have been an apparent increase in osteoclast number in the biopsies because of impaired efferocytosis of abnormal osteoclasts; the phagocytes that should be recruited to dispose of the apoptotic osteoclasts may themselves be inhibited by AL present in the bone microenvironment [32, 33] . It is possible that impaired osteoclast differentiation may predominate in the early course of BP therapy and the in vivo accumulation of apoptotic and dysfunctional osteoclasts may prevail with prolonged treatment.
This study shows that AL in vivo is associated with reduced pro-osteoclastogenic RANKL and elevated antiosteoclastogenic factor OPG in bone marrow. There is some information about clinical effects of AL on these factors. Dobnig et al. [34] demonstrated a significant increase in serum levels of OPG in osteoporotic women who were treated with AL or risedronate for 6 and 12 months. They reported that sRANKL levels remained unchanged at those times. D'Amelio et al. [35] showed that after 3 months of treatment with risedronate, the number and activity of osteoclasts generated from peripheral blood mononuclear cells were significantly lower compared with a control group. They suggested that risedronate is able to reduce osteoclast recruitment from peripheral blood, probably by altered production of regulatory cytokines. For a group of patients with Paget disease, Martini et al. [36] reported increases in OPG levels in blood after 3 and 6 months treatment with pamidronate. They also showed a trend toward a decrease in RANKL levels. Other data suggest that circulating OPG may reflect OPG activity in the bone [37, 38] . Given that OPG is a secreted molecule produced by MSCs and osteoblasts, it is conceivable that the circulating level of OPG is a meaningful indicator of the effects of BPs on bone marrow. The RANKL/OPG ratio is considered by many to be useful to monitor clinical suppression of osteoclastic bone resorption by BPs [34] [35] [36] .
Our data indicate that in addition to direct stimulation of osteoclasts, M-CSF may downregulate the expression of OPG in human BMCs. M-CSF was shown to be an important factor for the survival of osteoclasts and, in fact, is one of the mediators produced by osteoblasts and stromal cells that regulate osteoclasts [19] [20] [21] . Yamada et al. [39] reported that M-CSF suppresses the production of OPG in mouse bone marrow macrophages and may act to increase the sensitivity of osteoclast progenitors to RANKL. Many of the agents that stimulate osteoclast development, like 1,25-dihydroxyvitamin D and interleukins, act through a dual capacity to stimulate RANKL and inhibit OPG [40] . The data presented herein indicate that BPs act in reverse. This culture system intentionally does not include supplements that promote osteoblast differentiation, i.e., dexamethasone, b-glycerophosphate, and ascorbate-phosphate. Evidence suggests that MSCs [41] and osteoblasts [42] support osteoclast differentiation by producing regulatory factors and that the RANKL/OPG ratio varies under different conditions [8] . The data presented herein demonstrate that constitutive levels of expression of RANKL and OPG in marrow depend on whether the subject had been treated with AL.
In the second part of this study, we tested whether AL directly affected RANKL, OPG, and M-CSF expression in cultures of adherent hMSCs. There is no obvious explanation for the range of basal expression in this series of hMSCs from postmenopausal women who met the inclusion criteria, but it may reflect the range of inherent rates of bone turnover. The effect of AL in the nine samples of MSCs tested here was related to the basal level of gene expression. AL's inhibition of RANKL was more consistent in samples that had higher basal levels of RANKL. More information may be gained by evaluation of other marrow cells, such as lymphocytes. Eghbali-Fatourechi et al. [43] noted that expression of RANKL in MSCs, as well as in marrow-derived T and B cells, was related to bone turnover, age, and estrogen status of the subject. The effects of AL on human marrow cells may be different from those reported for murine cells, for osteoblasts, or for other N-BPs. Nishida et al. [44] demonstrated that minodronic acid inhibited osteoclast formation by downregulating RANKL in murine ST2 stromal cells. Using murine calvarial osteoblasts, however, Kim et al. [45] reported that the inhibitory action of AL and pamidronate on bone resorption did not involve the expression of RANKL and OPG after 1 day of treatment; after 2 days, RANKL was unexpectedly increased by both N-BPs and OPG expression was slightly increased by 10 -7 and 10 -6 M of pamidronate. Because of the resulting increase, rather than decrease, in the ratio of RANKL/OPG, the authors suggested that RANKL and OPG may not be the mechanism by which BPs inhibit bone resorption. On the other hand, Viereck et al. [46] reported that zoledronic acid and pamidronate upregulated OPG expression in primary human osteoblasts after 3 days. Pan et al. [47] showed that treatment of primary human osteoblasts with zoledronate led to a significant decrease in the expression of transmembrane RANKL and a significant increase in the level of secreted OPG. Mackie et al. [48] reported that pamidronate downregulated RANKL in UMR-106 rat osteosarcoma cells and had no effect on OPG expression. Kobayashi et al. [49] showed that AL inhibited secretion of dexamethasone-induced sRANKL protein by MG-63 cells, a line of human osteosarcoma cells. Other cytokines, such as TNF [50] , are involved in modulating osteoclast differentiation but were not evaluated in this study.
In conclusion, these studies demonstrate that marrow from subjects receiving AL had lower in vitro differentiation of osteoclasts and altered expression of the osteoclast regulatory factors RANKL and OPG compared with marrow from age-and gender-matched controls. These results show that osteoclast differentiation is dysregulated in marrow isolated from subjects receiving AL. These findings show that AL has inhibitory effects on osteoclast differentiation in addition to its known action to promote apoptosis of mature osteoclasts. Furthermore, this study affirms the usefulness of human bone marrow cultures to investigate at the cellular level the clinical effects of therapeutic interventions.
